Keytruda

• Women of reproductive potential are advised to use an effective contraception during the treatment with pembrolizumab and should continue the contraception for at least four months after the last dose of pembrolizumab to avoid pregnancy. • Breastfeeding mothers should not breastfeed their children during pembrolizumab treatment and for at least four months after stopping pembrolizumab. • Patients should consult their physician immediately for managing the condition appropriately if any serious side effects, or symptoms and signs of any illnesses occur. • • A condition of colitis with severe loose stools and stomach pain • • Hepatitis or symptoms and signs of jaundice with nausea or vomiting • • Infection of the airways with cough, chest pain, and difficulty in breathing • • Symptoms and signs of the following • • Thyroid disorders • • Type 1 diabetes • • Nephritis or swelling of the kidneys • Administering steroids and hormone replacement therapy can be considered if patients experience any symptoms and signs of pituitary disorders such as hypopituitarism or hypophysitis. • Pembrolizumab can lead to life-threatening infusion-related reactions such as serious allergic reactions along with wheezing, rashes, itching, low blood pressure, and chills. In such cases, the pembrolizumab infusion can be stopped permanently. • Patients taking pembrolizumab should not receive live vaccines such as BCG, mumps, measles, rubella, and yellow fever during the treatment and for at least six months after the last dose of pembrolizumab because the vaccines may not offer full protection. • Patients should be given pembrolizumab only in a hospital setting and must be monitored closely particularly during administration to manage any complications.